{"id":61901,"date":"2026-03-30T22:05:05","date_gmt":"2026-03-30T14:05:05","guid":{"rendered":"https:\/\/flcube.com\/?p=61901"},"modified":"2026-03-30T22:05:06","modified_gmt":"2026-03-30T14:05:06","slug":"salubris-pharma-licenses-sintanovos-peripherally-restricted-kor-agonist-stc007-for-pruritus-and-pain-across-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61901","title":{"rendered":"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China"},"content":{"rendered":"\n<p><strong>Shenzhen Salubris Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002294:SHE\">SHE: 002294<\/a>) announced an exclusive licensing agreement with <strong>Chengdu-based Sintanovo<\/strong> for <strong>STC007<\/strong>, a <strong>peripheral kappa opioid receptor (KOR) agonist<\/strong>, granting Salubris full rights across <strong>Greater China<\/strong> (Mainland China, Hong Kong, Macau, and Taiwan) for <strong>all pruritus indications<\/strong>\u2014including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system\u2013penetrant molecule is designed to <strong>avoid classic opioid side effects<\/strong> such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for <strong>moderate-to-severe chronic itch<\/strong> and <strong>post-surgical pain<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-territory\">Deal Structure &amp; Territory<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Sintanovo (Chengdu, China)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Salubris Pharmaceuticals<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>STC007 (peripheral KOR agonist)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td><strong>Greater China<\/strong> (Mainland, HK, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Indications Covered<\/strong><\/td><td><strong>All pruritus-related uses<\/strong> (broadly defined)<\/td><\/tr><tr><td><strong>Rights Included<\/strong><\/td><td>Development, regulatory, manufacturing, commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The agreement excludes central-acting indications, aligning with STC007\u2019s <strong>peripheral selectivity profile<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: <strong>Kappa opioid receptor (KOR)<\/strong> on peripheral sensory neurons<\/li>\n\n\n\n<li><strong>Key Feature<\/strong>: <strong>Does not readily cross the blood-brain barrier (BBB)<\/strong><\/li>\n\n\n\n<li><strong>Safety Advantage<\/strong>: Avoids CNS-mediated adverse effects of traditional opioids:<\/li>\n\n\n\n<li>No respiratory depression<\/li>\n\n\n\n<li>No constipation<\/li>\n\n\n\n<li>Low abuse\/addiction potential<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: KOR activation inhibits <strong>pruriceptive signaling<\/strong> and <strong>nociception<\/strong> at the site of injury or inflammation<\/li>\n<\/ul>\n\n\n\n<p>This mechanism is particularly relevant in <strong>chronic kidney disease\u2013associated pruritus (CKD-aP)<\/strong>, a debilitating condition affecting <strong>~40% of hemodialysis patients<\/strong> with limited treatment options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-status\">Clinical Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ongoing Trials in Mainland China<\/strong>:<\/li>\n\n\n\n<li><strong>Phase II<\/strong>: Moderate-to-severe pruritus in <strong>adult hemodialysis patients with CKD<\/strong><\/li>\n\n\n\n<li><strong>Additional Study<\/strong>: Post-<strong>abdominal surgery pain<\/strong> management<\/li>\n\n\n\n<li><strong>Primary Endpoints<\/strong>: Itch severity reduction (WI-NRS), rescue medication use, safety\/tolerability<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: First peripherally restricted KOR agonist in late-stage development in China for pruritus<\/li>\n<\/ul>\n\n\n\n<p>If successful, STC007 could become the <strong>first non-immunosuppressive, non-opioid systemic therapy<\/strong> approved specifically for CKD-aP in Greater China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-salubris\">Strategic Rationale for Salubris<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong>: Complements Salubris\u2019s existing CNS and cardiovascular franchises with a <strong>novel peripheral neuro-modulator<\/strong><\/li>\n\n\n\n<li><strong>High-Unmet-Need Indications<\/strong>: CKD-aP affects <strong>>500,000 dialysis patients in China<\/strong>; post-surgical pain remains undertreated due to opioid risks<\/li>\n\n\n\n<li><strong>Commercial Readiness<\/strong>: Leverages Salubris\u2019s <strong>established hospital sales force<\/strong> and <strong>regulatory expertise<\/strong> to accelerate launch<\/li>\n<\/ul>\n\n\n\n<p>The deal follows Salubris\u2019s strategy of <strong>in-licensing differentiated mechanisms<\/strong> from domestic innovators to de-risk R&amp;D while capturing first-mover advantages.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD-aP Market<\/strong>: Estimated <strong>\u00a53\u20135 billion ($430\u2013720M)<\/strong> annual value in China by 2028<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Only <strong>difelikefalin (IV)<\/strong> approved globally for CKD-aP; no oral alternatives available<\/li>\n\n\n\n<li><strong>Pricing Power<\/strong>: Novel mechanism and strong safety profile support premium reimbursement<\/li>\n<\/ul>\n\n\n\n<p>With hemodialysis centers concentrated in urban hospitals, Salubris can achieve rapid adoption through targeted specialty detailing.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical outcomes, regulatory approval, and commercial performance. Actual results may vary due to trial data, NMPA review, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[335,1167,4667],"class_list":["post-61901","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-salubris-pharmaceuticals","tag-she-002294","tag-sintanovo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo for STC007, a peripheral kappa opioid receptor (KOR) agonist, granting Salubris full rights across Greater China (Mainland China, Hong Kong, Macau, and Taiwan) for all pruritus indications\u2014including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system\u2013penetrant molecule is designed to avoid classic opioid side effects such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for moderate-to-severe chronic itch and post-surgical pain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61901\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo for STC007, a peripheral kappa opioid receptor (KOR) agonist, granting Salubris full rights across Greater China (Mainland China, Hong Kong, Macau, and Taiwan) for all pruritus indications\u2014including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system\u2013penetrant molecule is designed to avoid classic opioid side effects such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for moderate-to-severe chronic itch and post-surgical pain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61901\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T14:05:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T14:05:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61901#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61901\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China\",\"datePublished\":\"2026-03-30T14:05:05+00:00\",\"dateModified\":\"2026-03-30T14:05:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61901\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Salubris Pharmaceuticals\",\"SHE: 002294\",\"Sintanovo\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61901#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61901\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61901\",\"name\":\"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-30T14:05:05+00:00\",\"dateModified\":\"2026-03-30T14:05:06+00:00\",\"description\":\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo for STC007, a peripheral kappa opioid receptor (KOR) agonist, granting Salubris full rights across Greater China (Mainland China, Hong Kong, Macau, and Taiwan) for all pruritus indications\u2014including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system\u2013penetrant molecule is designed to avoid classic opioid side effects such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for moderate-to-severe chronic itch and post-surgical pain.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61901#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61901\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61901#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo for STC007, a peripheral kappa opioid receptor (KOR) agonist, granting Salubris full rights across Greater China (Mainland China, Hong Kong, Macau, and Taiwan) for all pruritus indications\u2014including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system\u2013penetrant molecule is designed to avoid classic opioid side effects such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for moderate-to-severe chronic itch and post-surgical pain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61901","og_locale":"en_US","og_type":"article","og_title":"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China","og_description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo for STC007, a peripheral kappa opioid receptor (KOR) agonist, granting Salubris full rights across Greater China (Mainland China, Hong Kong, Macau, and Taiwan) for all pruritus indications\u2014including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system\u2013penetrant molecule is designed to avoid classic opioid side effects such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for moderate-to-severe chronic itch and post-surgical pain.","og_url":"https:\/\/flcube.com\/?p=61901","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-30T14:05:05+00:00","article_modified_time":"2026-03-30T14:05:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61901#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61901"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China","datePublished":"2026-03-30T14:05:05+00:00","dateModified":"2026-03-30T14:05:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61901"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Salubris Pharmaceuticals","SHE: 002294","Sintanovo"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61901#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61901","url":"https:\/\/flcube.com\/?p=61901","name":"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-30T14:05:05+00:00","dateModified":"2026-03-30T14:05:06+00:00","description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo for STC007, a peripheral kappa opioid receptor (KOR) agonist, granting Salubris full rights across Greater China (Mainland China, Hong Kong, Macau, and Taiwan) for all pruritus indications\u2014including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system\u2013penetrant molecule is designed to avoid classic opioid side effects such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for moderate-to-severe chronic itch and post-surgical pain.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61901#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61901"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61901#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Salubris Pharma Licenses Sintanovo\u2019s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61901"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61901\/revisions"}],"predecessor-version":[{"id":61903,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61901\/revisions\/61903"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}